Last updated: July 8, 2026
ecutive summary: ABRAXIS BIOSCIENCE, LLC v. CIPLA LTD., case 2:16-cv-09074, is a Hatch-Waxman patent dispute tied to Abraxane (paclitaxel protein-bound particles, albumin-bound). The docket centers on infringement/non-infringement and invalidity positions for Cipla’s proposed generic/alternative version and the asserted Abraxane patent estate, with a litigation posture focused on resolving 35 U.S.C. § 271(e)(2) exposure and the timeliness/validity of the asserted claims. A complete litigation summary with asserted patent numbers, claims, settlement terms, and procedural dates cannot be produced from the case identifier alone.
What patents are asserted in ABRAXIS BIOSCIENCE v. CIPLA Ltd. 2:16-cv-09074?
Answer (high level): The case is a patent litigation involving Abraxane and Cipla’s attempted market entry, but the asserted patent identifiers, claim numbers, and case-specific theories are not provided by the case caption and docket number alone.
Which Abraxane patent estate is targeted in the infringement allegations?
Common Abraxane litigation targets (when asserted in comparable Abraxane generic disputes) include:
- Composition of matter or formulation patents on albumin-bound paclitaxel (including particle/size range and albumin binding characteristics).
- Method-of-use or manufacturing/process patents tied to producing stable albumin-bound particles.
- Secondary patents (e.g., related to stability, reconstitution, or specific process parameters).
What is the typical 35 U.S.C. § 271(e)(2) theory in these Abraxane cases?
In Hatch-Waxman disputes over complex formulation drugs, plaintiffs typically argue that the ANDA AND the proposed manufacturing and formulation steps fall within the scope of asserted claims under § 271(e)(2), even before approval.
What procedural posture does ABRAXIS v. CIPLA follow in 2:16-cv-09074?
Answer (high level): The matter is filed in federal court and proceeds through the standard phases of claim construction, dispositive motion practice, and potential trial or settlement. Exact dates and outcomes require docket-level filings.
What happens in the early stage of Abraxane formulation patent suits?
Typical phases include:
- Complaint and infringement contentions.
- Answer, defenses (invalidity, non-infringement, lack of willfulness, unenforceability).
- Claim construction briefs and Markman order.
- Summary judgment or Daubert motions.
- Pretrial and trial setting, or resolution via settlement.
When does ABRAXIS v. CIPLA reach key milestones (Markman, summary judgment, trial or settlement)?
Answer (high level): The case timeline cannot be stated precisely without the docket’s order list and entry dates.
Key milestones that determine market entry risk
In Abraxane-type disputes, milestones that drive launch and exclusivity leverage include:
- Claim construction narrowing that can either preserve or cut off asserted coverage.
- Summary judgment resolving obviousness or lack of enablement-type invalidity theories.
- Any stipulation of non-infringement under amended formulations.
- Entry of judgment or a settlement that triggers an agreed launch date.
How do courts analyze infringement for albumin-bound paclitaxel formulation patents in CIPLA disputes?
Answer (high level): Courts apply claim construction to formulation/process parameters and then test whether the proposed product meets each claim limitation. For complex particles, infringement analysis often turns on:
- Particle size/distribution and morphology.
- Albumin binding state and stability.
- Process steps and ranges (e.g., mixing conditions, purification steps, solvent removal profiles).
- Reconstitution behavior and functional characteristics.
What evidence matters most
- Expert declarations comparing the ANDA product’s technical data with patent claim limits.
- Manufacturing records or batch characterization data for the proposed product.
- Prior art experiments in invalidity and enablement challenges.
How strong is the asserted Abraxane patent estate in ABRAXIS v. CIPLA-type disputes?
Answer (high level): Strength depends on the specific asserted patents, the construed claim scope, and the invalidity grounds (anticipation/obviousness/indefiniteness/enablement). Those details are not available from the case identifier.
Common invalidity arguments in formulation patent litigation
- Obviousness over prior paclitaxel nanoparticle or albumin-bound formulations.
- Lack of written description for claimed ranges or characteristics.
- Indefiniteness tied to ambiguous parameter definitions (size distribution, “stable,” “substantially”).
- Enablement where the specification does not support breadth across the claim range.
What Paragraph IV challenges and FDA Orange Book events connect to this litigation?
Answer (high level): This is a Hatch-Waxman infringement suit linked to an FDA submission referencing Abraxane’s Orange Book listing. The specific patents listed for Abraxane and which were the subject of the Paragraph IV are not stated here.
What buyers and investors need from the Orange Book link
For high-confidence launch-risk analysis, the core inputs are:
- The Orange Book patent numbers tied to the case.
- Whether the challenge was “high 1, high 2, or low 1” category.
- Expiration of each listed patent versus any granted exclusivity (3-year/7.5-year/market exclusivity type, depending on the submission history).
- Whether a court-triggered 30-month stay was in play.
Did ABRAXIS and CIPLA reach settlement terms, and what launch date did they lock?
Answer (high level): Settlement outcomes are not available from the case identifier alone.
What settlement terms usually control in Abraxane cases
When Abraxane disputes settle, terms often include:
- A date certain for launch.
- Carve-outs tied to non-infringing variants or specific product parameters.
- Payment or license structure.
- Stipulations regarding dismissal and continued prosecution of non-asserted claims.
What verdicts or judgments did the court enter in 2:16-cv-09074?
Answer (high level): Judgment details require docket orders and any opinion text, which are not provided here.
How to interpret outcomes for generic/next-gen competitors
- A validity win strengthens the barrier to entry across the product category.
- An infringement win without damages still can block approval unless a design-around is available.
- A settlement can create a de facto launch timeline even without a merits decision.
How does ABRAXIS v. CIPLA compare with other Abraxane generic patent suits?
Answer (high level): Comparative analysis depends on which patents were asserted in each case and how courts construed key formulation limitations. The asserted-patent list for 2:16-cv-09074 is not provided, preventing a credible comparison.
What to benchmark across related cases
- Same patent numbers across multiple plaintiffs and generic filers.
- Claim construction consistency (particularly for particle size/binding/stability elements).
- Repeated invalidity outcomes for the same prior art references.
- Whether courts treat process patents as product-limiting or proof-of-method only.
Key Takeaways
- ABRAXIS BIOSCIENCE, LLC v. CIPLA LTD., case 2:16-cv-09074, is a patent infringement action tied to Abraxane and a contested market entry effort.
- A complete litigation summary with asserted patent numbers, claim scope, procedural milestones, and any settlement or judgment cannot be produced from the case caption and docket number alone.
- Actionable risk analysis for generic entry, licensing, and litigation strategy requires docket-level details: asserted patents, Orange Book mapping, claim construction results, and final case disposition.
FAQs
- What is the typical relief sought by Abraxane formulation plaintiffs in Hatch-Waxman suits like 2:16-cv-09074?
- How do claim construction orders affect infringement outcomes for albumin-bound paclitaxel particle patents?
- What invalidity defenses are most common for formulation/process patents covering nanoparticle drugs?
- How do 30-month stays and court outcomes translate into launch timing for Paragraph IV filers?
- When settlements occur in Abraxane cases, what product-design parameters are most often used for carve-outs?
References
- ABRAXIS BIOCIENCE, LLC v. CIPLA LTD., No. 2:16-cv-09074 (Docket identifier provided by user).
